IP Library Granted Patent US 10,285,989
Granted Patent B2
US 10,285,989 · App. 15/573,858 · Granted May 14, 2019

Pyrimidinone amide compounds as PDE2 inhibitors

Inventors: Dong-Ming Shen (Edison, NJ); Deping Wang (Furlong, PA); XiaoXia Qian (New York, NY); Bart Harper (New York, NY); Meng Yang (Westfield, NJ); Yingjian Bo (Beijing, CN)
Assignee: Merck Sharp & Dohme Corp.
A61K31/513A61P25/06A61P25/16A61P25/18A61P25/22A61P25/28C07D239/38C07D239/42C07D239/52C07D401/12C07D403/04C07D403/12C07D405/12C07D487/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,285,989
App. No.
15/573,858
Granted
May 14, 2019
Kind
B2
Abstract

The present invention is directed to pyrimidinone amide compounds which may be useful as therapeutic agents for the treatment of central nervous system and/or peripheral disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Alzheimer's, cognitive impairment, anxiety, depression, migraines, or Huntington's disease, Parkinson's disease, Parkinson's disease dementia (PDD), and other diseases associated with striatal hypofunction or basal ganglia dysfunction.

Claims (233)

1. A compound represented by structural formula I:

or a pharmaceutically

acceptable salt thereof,

wherein:

R 1 is linked to the pyrimidinone via an atom other than carbon and is selected from the group consisting of halo, —OR, O(CH 2 ) 1-3 OR, O(CH 2 ) 1-3 N(R) 2 , O(CH 2 ) n C(R) 2 OR, O-(CH 2 ) n C 4-10 heterocyclyl, O-(CH 2 ) 1-3 OC 6-10 aryl, O—C 6-10 aryl, N(R x ) 2 , —NRC 5-10 heterocyclyl, —NRC 6-10 aryl, —NRC 3-10 cycloalkyl, SR, said alkyl, cycloalkyl, heterocyclyl and aryl optionally substituted with one to three groups of R a ;

R 1a represents H, or C 1-6 alkyl, said alkyl optionally substituted with OH or halo,

R 2 and R 3 are independently selected from the group consisting of hydrogen, C 1-6 alkyl, (CH 2 ) n CN, C(O)R, C(O)OR, CF 3 , —C 3-10 cycloalkyl, C 6-10 aryl, C 5-10 heteroaryl, said alkyl, cycloalkyl, aryl and heteroaryl optionally substituted with one to three groups of R b ;

R 2 and R 3 can combine with the carbon atom to which they are attached to form a C 3-6 cycloalkyl, said cycloalkyl optionally interrupted with 1-2 heteroatoms selected from O, S, or N and optionally substituted with one to three groups of R b

R 4 represents hydrogen, halo, or C 1-6 alkyl; or alternatively,

R 2 and R 3 along with the carbon atom to which they are attached and the R 4 on the phenyl ring can combine to form a C6-10 bicyclic ring which includes the phenyl ring, said bicyclic ring optionally interrupted with 1-2 heteroatoms selected from O, S, and N and optionally substituted with one to three groups of R b ;

R represents H, or C 1-6 alkyl;

R a is selected from the group consisting of H, halo, CN, C 1-6 alkyl, (CH 2 ) n OR, (O) p C 1-4 haloalkyl, S(O) s CF 3 , S(O) s R, SF 5 , C 3-10 cycloalkyl, said alkyl and cycloalkyl optionally substituted with one to three groups of R b ;

R b is selected from the group consisting of H, halo, C 1-6 alkyl, SO 2 C 1-6 alkyl, and (O) p C 1-4 haloalkyl;

each occurring R x independently represents H, or C 1-6 alkyl, or two adjacent R x groups can combined together with the nitrogen atom to which they are attached to form a C 4-10 heterocyclyl optionally substituted with one to three groups of R b ;

n represents 0, 1, 2, 3, or 4;

s represents 0, 1, or 2; and

p represents 0 or 1.

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof wherein R 1a is hydrogen.

3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 is selected from the group consisting of OR, O(CH 2 ) 1-3 OR, O(CH 2 ) n C(R) 2 OR, and O(CH 2 ) 1-3 N(R) 2 and optionally substituted O—(CH 2 ) n C 4-10 heterocyclyl said heterocyclyl is selected from the group consisting of oxetanyl, tetrahydrofuranyl, piperidinyl, pyrrolidinyl, morpholinyl, dihydropyrrolopyrazolyl, dihydropyrrolopyrimindyl, tetrahydropyranyl, pyrazolyl, and azetidinyl.

4. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 is selected from the group N(R x ) 2 , —NRC 5-10 heterocyclyl, —NRC 6-10 aryl, and NRC 3-10 cycloalkyl, said cycloalkyl, aryl and heterocyclyl optionally substituted with one to three groups of R a .

5. The compound according to claim 4 or a pharmaceutically acceptable salt thereof wherein R 1 is N(R x ) 2 and the two adjacent R x groups are combined together with the nitrogen atom to which they are attached to form a C 4-10 heterocyclyl selected from the group consisting of optionally substituted pyrrolidinyl, pyrazolyl, azetidinyl, piperidinyl, morpholinyl, dihydropyrrolopyrazolyl, dihydropyrrolopyrimidinyl, and dihydropyrrolopyridinyl.

6. The compound according to claim 3 or a pharmaceutically acceptable salt thereof wherein R 1 is O-(CH 2 ) n C 4-10 heterocyclyl, said heterocyclyl optionally substituted with one to three groups of R a .

7. The compound according to claim 1 or a pharmaceutically acceptable salt thereof wherein R 1 is selected from the group consisting of SCH 3 , —N(CH 3 ) 2 , N(CH 3 )(CH 2 CH 3 ), N(CH 2 CH 3 ) 2 , —NH 2 , —NHCH 3 , NH-cyclobutyl, NH-cyclopentyl, NH-cyclopropyl, NH-pyridyl, —OR, —O-phenyl, —O(CH 2 ) 2 OCH 3 , —O(CH 2 ) 3 OCH 3 , —O(CH 2 ) 3 OCH(CH 3 ) 2 , —O(CH 2 ) 2 N(CH 3 ) 2 , —O(CH 2 ) 2 C(CH 3 ) 2 OCH 3 , —OCH 2 oxetanyl, —O(CH 2 ) 4 OCH 3 , —O(CH 2 ) 3 NHCH 3 , —O-tetrahydrofuranyl, —O-piperidinyl, —O-oxetanyl, —O(CH 2 ) 3 Ophenyl, O(CH 2 ) 2 CH(CH 3 )OCH 3 , —O-tetrahydropyranyl, O-pyrrolidinyl, N linked pyrazolyl, N linked azetidinyl, N linked pyrrolidinyl, and N linked piperidinyl, said cyclobutyl, cyclopentyl, cyclopropyl, phenyl, oxetanyl, tetrahydrofuranyl, piperidinyl, tetrahydropyranyl, pyrollidinyl, pyrazolyl, and azetidinyl optionally substituted with one to three groups of R a .

8. The compound according to claim 7 or a pharmaceutically acceptable salt thereof wherein R 1 is selected from N(CH 3 ) 2 , N(CH 3 )(CH 2 CH 3 ), N(CH 2 CH 3 ) 2 , —NH 2 , —NHCH 3 , and optionally substitiuted NH-cyclobutyl, NH-cyclopentyl, NH-cyclopropyl, and NH-pyridyl.

9. The compound according to claim 8 or a pharmaceutically acceptable salt thereof wherein R 1 is selected from N(CH 3 ) 2 .

10. The compound according to claim 1 or a pharmaceutically acceptable salt thereof wherein one of R 2 and R 3 is hydrogen or CH 3 and the other is C 1-6 alkyl or C 3-10 cycloalkyl, said alkyl and cycloalkyl optionally substituted with one to three groups of R b .

11. The compound according to claim 10 or a pharmaceutically acceptable salt thereof wherein the C 1-6 alkyl is selected from the group consisting of CH 3 , CH(CH 3 ) 2 , CH 2 CH 3 , C(CH 3 ) 3 and the optionally substituted C 3-10 cycloalkyl is selected from cyclopropyl, cyclobutyl, and cyclopentyl.

12. The compound according to claim 11 or a pharmaceutically acceptable salt thereof wherein the C 1-6 alkyl is selected from the group consisting of CH 3 , CH(CH 3 ) 2 , and CH 2 CH 3 , and the optionally substituted C 3-10 cycloalkyl is cyclopropyl.

13. The compound according to claim 1 or a pharmaceutically acceptable salt thereof wherein R 2 and R 3 combine with the carbon atom to which they are attached to form a C 3-10 cycloalkyl, said cycloalkyl optionally substituted with one to three groups of R b .

14. The compound according to claim 13 wherein the C 3-10 cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, and cyclopentyl.

15. The compound according to claim 1 or a pharmaceutically acceptable salt thereof wherein R a is selected from OH, halo, CH 3 , optionally substituted cyclopropyl, (CH 2 ) n OCH 3 , CH 2 F, (CH 2 ) n CF 3 , OCHF 2 , OCF 3 , SCH 3 , SCF 3 , SF 5 , SOCF 3 , SO 2 CF 3 , SO 2 CH 3 , CH 2 NH 2 , and (CH 2 ) n N(CH 3 ) 2 .

16. The compound according claim 1 or a pharmaceutically acceptable salt thereof represented by structural formula II:

wherein R 1 is selected from the group consisting of —N(CH 3 ) 2 , NH 2 , NHCH 3 , O(CH 2 ) 3 NHCH 3 , and optionally substituted O-tetrahydrofuranyl, N linked pyrazolyl, N linked pyrrolidinyl, O-pyrrolidinyl, or O-piperidinyl, R 3 is selected from the group consisting of CH 3 , CH(CH 3 ) 2 , CH 2 CH 3 , C(CH 3 ) 3 and optionally substituted cyclopropyl, and R a is selected from the group consisting of SCF 3 , CF 3 , OCF 2 , OCF 3 , and CH 2 CF 3 .

17. A compound which is:

N-(1-(3-fluoro-4-(trifluoromethyl)phenyl)cyclopropyl)-6-oxo-2-(pyrrolidin-1-yl)-1,6-dihydropyrimidine-4-carboxamide,

(R)-N-(2,2-dimethyl-1-(4-(trifluoromethyl)phenyl)propyl)-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

(R)-N-(1-(3-chloro-4-(trifluoromethoxy)phenyl)ethyl)-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

(R)-N-(cyclopropyl(4-(pentafluoro-λ 6 -sulfanyl)phenyl)methyl)-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

(R)-2-(dimethylamino)-6-oxo-N-(1-(4-(pentafluoro-λ 6 -sulfanyl)phenyl)propyl)-1,6-dihydropyrimidine-4-carboxamide,

(R)-6-oxo-2-(pyrrolidin-1-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl)-1,6-dihydropyrimidine-4-carboxamide,

(R)-2-(4-methyl-1H-pyrazol-1-yl)-6-oxo-N-(1-(4-(trifluoromethyl)phenyl)ethyl)-1,6-dihydropyrimidine-4-carboxamide,

(R)-2-(3-methyl-1H-pyrazol-1-yl)-6-oxo-N-(1-(4-(trifluoromethyl)phenyl)ethyl)-1,6-dihydropyrimidine-4-carboxamide,

(R)-6-oxo-2-(1H-pyrazol-1-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl)-1,6-dihydropyrimidine-4-carboxamide,

(R)-2-(azetidin-1-yl)-6-oxo-N-(1-(4-(trifluoromethyl)phenyl)ethyl)-1,6-dihydropyrimidine-4-carboxamide,

2-((R)-3-fluoropyrrolidin-1-yl)-6-oxo-N-((R)-1-(4-(trifluoromethyl)phenyl)ethyl)-1,6-dihydropyrimidine-4-carboxamide,

2-((S)-3-fluoropyrrolidin-1-yl)-6-oxo-N-((R)-1-(4-(trifluoromethyl)phenyl)ethyl)-1,6-dihydropyrimidine-4-carboxamide,

(R)-2-(3,3-difluoropyrrolidin-1-yl)-6-oxo-N-(1-(4-(trifluoromethyl)phenyl)ethyl)-1,6-dihydropyrimidine-4-carboxamide,

N-((R)-2,2-dimethyl-1-(4-(trifluoromethyl)phenyl)propyl)-2-(3-(methoxymethyl)pyrrolidin-1-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

(R)-2-(methylthio)-6-oxo-N-(1-(4-(trifluoromethyl)phenyl)ethyl)-1,6-dihydropyrimidine-4-carboxamide,

(S)-2-(methylthio)-6-oxo-N-(1-(4-(trifluoromethyl)phenyl)ethyl)-1,6-dihydropyrimidine-4-carboxamide,

(R)-2-methoxy-6-oxo-N-(1-(4-(trifluoromethyl)phenyl)ethyl)-1,6-dihydropyrimidine-4-carboxamide,

(R)-2-ethoxy-6-oxo-N-(1-(4-(trifluoromethyl)phenyl)ethyl)-1,6-dihydropyrimidine-4-carboxamide,

(R)-6-oxo-2-phenoxy-N-(1-(4-(trifluoromethyl)phenyl)ethyl)-1,6-dihydropyrimidine-4-carboxamide,

(R)-2-hydroxy-N-(2-methyl-1-(4-((trifluoromethyl)thio)phenyl)propyl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(2-Methoxyethoxy)-6-oxo-N-(1-(4-(trifluoromethyl)phenyl)ethyl)-1,6-dihydropyrimidine-4- carboxamide,

(R)-2-(3,4-dimethoxyphenoxy)-6-oxo-N-(1-(4-(trifluoromethyl)phenyl)ethyl)-1,6-dihydropyrimidine-4-carboxamide,

2-(3-Fluoroazetidin-1-yl)-6-oxo-N-{(1R)-1[4-(trifluoromethyl)phenyl]ethyl}-1,6-dihydropyrimidine-4-carboxamide,

2-(3,3-Difluoroazetidin-1-yl)-6-oxo-N-{(1R)-1-[4-(trifluoromethyl)phenyl]ethyl}-1,6-dihydropyrimidine-4-carboxamide,

N-{(R)-cyclopropyl[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-6-oxo-2-pyrrolidin-1-yl-1,6-dihydropyrimidine-4-carboxamide,

N-{(R)-cyclopropyl[4-(trifluoromethyl)phenyl]methyl}-6-oxo-2-pyrrolidin-1-yl-1,6-dihydropyrimidine-4-carboxamide,

N-[(R)-cyclopropyl{4-[(trifluoromethyl)sulfanyl]phenyl}methyl]-6-oxo-2-pyrrolidin-1-yl-1,6-dihydropyrimidine-4-carboxamide,

6-oxo-2-pyrrolidin-1-yl-N-{(1R)-1-[4-(trifluoromethoxy)phenyl]ethyl}-1,6-dihydropyrimidine-4-carboxamide,

N-[(1R)-1-{3-fluoro-4-[(trifluoromethyl)sulfanyl]phenyl}propyl]-6-oxo-2-pyrrolidin-1-yl-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-[(1R)-2-methyl-1-{4-[(trifluoromethyl)sulfanyl]phenyl}propyl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-{(1R)-2,2-dimethyl-1-[4-(2,2,2-trifluoroethyl)phenyl]propyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(R)-cyclopropyl[4-(difluoromethoxy)phenyl]methyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(1R)-1-[4-(difluoromethoxy)phenyl]-2-methylpropyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(1R)-1-[4-(difluoromethoxy)phenyl]-2,2-dimethylpropyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-[(1R)-1-(4-cyclopropylphenyl)-2,2-dimethylpropyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(1R)-1-[2,5-difluoro-4-(trifluoromethyl)phenyl]ethyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-{(1R)-1-[2-fluoro-4-(trifluoromethyl)phenyl]-2,2-dimethylpropyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-{(1R)-2,2-dimethyl-1-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]propyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-{1,2-dimethyl-1-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]propyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-[(1R)-1-(4-cyclopropyl-3-fluorophenyl)ethyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-[(R)-[3-fluoro-4-(trifluoromethyl)phenyl](1-methylcyclopropyl)methyl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-{(R)-(1-methylcyclopropyl)[4-(trifluoromethyl)phenyl]methyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-[(R)-(4-tert-butylphenyl)(1-methylcyclopropyl)methyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-6-oxo-N-{1-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]cyclopropyl}-1,6-dihydropyrimidine-4-carboxamide,

N-[1-(4-tert-butylphenyl)cyclopropyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-{(1R)-2-methyl-1-[4-(trifluoromethyl)phenyl]propyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(1R)-1-[4-(difluoromethoxy)-3-fluorophenyl]-2-methylpropyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-{1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-[1-(4-tert-butoxyphenyl)cyclopropyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-6-oxo-N-{1-[4-(2,2,2-trifluoroethyl)phenyl]cyclopropyl}-1,6-dihydropyrimidine-4-carboxamide,

N-{1-[4-(difluoromethoxy)phenyl]cyclopropyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(R)-cyclopropyl[4-(difluoromethoxy)-3-fluorophenyl]methyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(1R)-1-[4-(difluoromethoxy)-3-fluorophenyl]-2,2-dimethylpropyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-[(R)-[4-(difluoromethoxy)-3-fluorophenyl](1-methylcyclopropyl)methyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-[(R)-cyclopropyl(4-cyclopropyl-3-fluorophenyl)methyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-{(R)-(1-methylcyclopropyl)[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-[(1R)-1-(4-cyclopropyl-3-fluorophenyl)-2,2-dimethylpropyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-[(R)-[4-(difluoromethyl)-3-fluorophenyl](1-methylcyclopropyl)methyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(1R)-1-[4-(difluoromethyl)phenyl]-2,2-dimethylpropyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-[(R)-[4-(difluoromethyl)phenyl](1-methylcyclopropyl)methyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(1R)-1-[4-(difluoromethyl)-3-fluorophenyl]-2,2-dimethylpropyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(1R)-1-[4-(difluoromethyl)phenyl]-2-methylpropyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(R)-cyclopropyl[4-(difluoromethyl)phenyl]methyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(1R)-1-[4-(difluoromethyl)-3-fluorophenyl]-2-methylpropyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(R)-cyclopropyl[4-(difluoromethyl)-3-fluorophenyl]methyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(1R)-1-[4-(difluoromethyl)phenyl]propyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(1R)-1-[4-(difluoromethyl)-3-fluorophenyl]propyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{1-[4-(difluoromethyl)-3-fluorophenyl]-1-methylethyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{1-[4-(difluoromethyl)-3-fluorophenyl]cyclopropyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-[(R)-(4-cyclopropylphenyl)(1-methylcyclopropyl)methyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-{(1S)-2,2-dimethyl-1-[4-(trifluoromethyl)phenyl]propyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(1R)-1-[4-(difluoromethyl)-2-fluorophenyl]-2,2-dimethylpropyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(1R)-1-[4-(1,1-difluoroethyl)phenyl]ethyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(1R)-1-[4-(1,1-difluoroethyl)phenyl]-2-methylpropyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(1R)-1-[4-(1,1-difluoroethyl)phenyl]-2,2-dimethylpropyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(1R)-1-[4-(1,1-difluoroethyl)-3-fluorophenyl]-2-methylpropyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-{1-methyl-1-[2-methyl-4-(trifluoromethyl)phenyl]ethyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-{1-[2-methoxy-4-(trifluoromethyl)phenyl]-1-methylethyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{1-[2-chloro-4-(trifluoromethyl)phenyl]-1-methylethyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-{1-[2-fluoro-4-(trifluoromethoxy)phenyl]-1-methylethyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-{1-[2-fluoro-4-(trifluoromethyl)phenyl]-1-methylethyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-{(1R)-1-[2-fluoro-4-(trifluoromethoxy)phenyl]ethyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(1R)-1-[2,3-difluoro-4-(trifluoromethyl)phenyl]ethyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-[(R)-[3-chloro-4-(trifluoromethoxy)phenyl](cyclopropyl)methyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(1R)-1-[3-chloro-4-(trifluoromethoxy)phenyl]-2-methylpropyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-6-oxo-N-{(1R)-1-[4-(trifluoromethoxy)phenyl]ethyl}-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-6-oxo-N-[(1R)-1-{4-[(trifluoromethyl)sulfanyl]phenyl}propyl]-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-6-oxo-N-{(1R)-1-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]ethyl}-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-{(1R)-1-[3-fluoro-4-(trifluoromethoxy)phenyl]ethyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-{(1R)-2-methyl-1-[4-(trifluoromethoxy)phenyl]propyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-6-oxo-N-(1-{4-[(trifluoromethyl)sulfanyl]phenyl}cyclopropyl)-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-{1-[3-fluoro-4-(trifluoromethyl)phenyl]-1-methylethyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-{1-[3-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(1R)-2-methyl-1-[4-(trifluoromethyl)phenyl]propyl}-6-oxo-2-pyrrolidin-1-yl-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-[(1R)-1-{3-fluoro-4-[(trifluoromethyl)sulfanyl]phenyl}ethyl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-[(R)-cyclopropyl{3-fluoro-4-[(trifluoromethyl)sulfanyl]phenyl}methyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-[(1R)-1-{3-fluoro-4-[(trifluoromethyl)sulfanyl]phenyl}propyl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(R)-cyclopropyl[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methyl}-6-oxo-2-pyrrolidin-1-yl-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-{(1R)-2,2-dimethyl-1-[4-(trifluoromethoxy)phenyl]propyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-{(1R)-1-[3-fluoro-4-(trifluoromethoxy)phenyl]-2,2-dimethylpropyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-{(1R)-1-[3-fluoro-4-(trifluoromethyl)phenyl]-2,2-dimethylpropyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-[(1R)-2,2-dimethyl-1-{4-[(trifluoromethyl)sulfanyl]phenyl}propyl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-{(1R)-1-[3-fluoro-4-(trifluoromethoxy)phenyl]propyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-6-oxo-N-{(1R)-1-[4-(trifluoromethoxy)phenyl]propyl}-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-{(1R)-1-[3-fluoro-4-(trifluoromethyl)phenyl]propyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(R)-cyclopropyl[4-(trifluoromethoxy)phenyl]methyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(R)-cyclopropyl[4-(trifluoromethyl)phenyl]methyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(R)-cyclopropyl[3-fluoro-4-(trifluoromethyl)phenyl]methyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(R)-cyclopropyl[3-fluoro-4-(trifluoromethoxy)phenyl]methyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-[(R)-cyclopropyl{4-[(trifluoromethyl)sulfanyl]phenyl}methyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-{(1R)-1-[3-fluoro-4-(trifluoromethyl)phenyl]-2-methylpropyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-[(R)-cyclopropyl(4-cyclopropylphenyl)methyl]-6-oxo-2-pyrrolidin-1-yl-1,6-dihydropyrimidine-4-carboxamide,

N-{(R)-cyclopropyl[4-(trifluoromethoxy)phenyl]methyl}-6-oxo-2-pyrrolidin-1-yl-1,6-dihydropyrimidine-4-carboxamide,

N-[(R)-cyclopropyl (4-cyclopropylphenyl)methyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

(R)-2-(dimethylamino)-N-(1-(4-(pentafluorothio)-2-fluorophenyl)ethyl)-6-oxo-1,6-dihydrop-yrimidine-4-carboxamide,

(S)-2-(dimethylamino)-N-(1-(4-(pentafluorothio)-2-fluorophenyl)ethyl)-6-oxo-1,6-dihydropy-rimidine-4-carboxamide,

2-(Dimethylamino)-N-{1-methyl-1-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]ethyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

(S)-2-(dimethylamino)-N-[{3-fluoro-4-[(trifluoromethyl)sulfanyl]phenyl}(1-methylcyclopropyl)methyl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

(R)-2-(dimethylamino)-N-[{3-fluoro-4-[(trifluoromethyl)sulfanyl]phenyl}(1-methylcyclopropyl)methyl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

(S)-2-(dimethylamino)-6-oxo-N-{1-[4-(2,2,2-trifluoro-1,1-dimethylethyl)phenyl]ethyl}-1,6-dihydropyrimidine-4-carboxamide,

(R)-2-(dimethylamino)-6-oxo-N-{1-[4-(2,2,2-trifluoro-1,1-dimethylethyl)phenyl]ethyl}-1,6-dihydropyrimidine-4-carboxamide,

(S)-2-(dimethylamino)-N-{1-[3-fluoro-4-(1-methylcyclopropyl)phenyl]-2,2-dimethylpropyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

(R)-2-(dimethylamino)-N-{1-[3-fluoro-4-(1-methylcyclopropyl)phenyl]-2,2-dimethylpropyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

(S)-2-(dimethylamino)-6-oxo-N-[1-{4-[1-(trifluoromethyl)cyclopropyl]phenyl}ethyl]-1,6-dihydropyrimidine-4-carboxamide,

(R)-2-(dimethylamino)-6-oxo-N-[1-{4-[1-(trifluoromethyl)cyclopropyl]phenyl}ethyl]-1,6-dihydropyrimidine-4-carboxamide,

(S)-2-(dimethylamino)-N-{1-[2-fluoro-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-2,2-dimethylpropyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

(R)-2-(dimethylamino)-N-{1-[2-fluoro-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-2,2-dimethylpropyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

(S)-2-(dimethylamino)-N-{1-[2-fluoro-4-(trifluoromethyl)phenyl]-1-methylpropyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

(R)-2-(dimethylamino)-N-{1-[2-fluoro-4-(trifluoromethyl)phenyl]-1-methylpropyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

6-oxo-2-piperidin-1-yl-N-{(1R)-1-[4-(trifluoromethyl)phenyl]ethyl}-1,6-dihydropyrimidine-4-carboxamide,

2-morpholin-4-yl-6-oxo-N-{(1 R)-1-[4-(trifluoromethyl)phenyl]ethyl}-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-6-oxo-N-{(1R)-1-[4-(trifluoromethyl)phenyl]ethyl}-1,6-dihydropyrimidine-4-carboxamide,

2-amino-6-oxo-N-{(1R)-1-[4-(trifluoromethyl)phenyl]ethyl}-1,6-dihydropyrimidine-4-carboxamide,

2-(methylamino)-6-oxo-N-{(1R)-1-[4-(trifluoromethyl)phenyl]ethyl}-1,6-dihydropyrimidine-4-carboxamide,

6-oxo-2-(pyridin-2-ylamino)-N-{(1R)-1-[4-(trifluoromethyl)phenyl]ethyl}-1,6-dihydropyrimidine-4-carboxamide,

2-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]-6-oxo-N-{(1R)-1- [4-(trifluoromethyl)phenyl]ethyl}-1,6-dihydropyrimidine-4-carboxamide,

2-(cyclobutylamino)-6-oxo-N-{(1R)-1-[4-(trifluoromethyl)phenyl]ethyl}-1,6-dihydropyrimidine-4-carboxamide,

2-(cyclopentylamino)-6-oxo-N-{(1R)-1-[4-(trifluoromethyl)phenyl]ethyl}-1,6-dihydropyrimidine-4-carboxamide,

2-(cyclopropylamino)-6-oxo-N-{(1R)-1-[4-(trifluoromethyl)phenyl]ethyl}-1,6-dihydropyrimidine-4-carboxamide,

2-[ethyl(methyl)amino]-6-oxo-N-{(1R)-1-[4-(trifluoromethyl)phenyl]ethyl}-1,6-dihydropyrimidine-4-carboxamide,

2-(diethylamino)-6-oxo-N-{(1R)-1-[4-(trifluoromethyl)phenyl]ethyl}-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-6-oxo-N-[(1R)-1-{4-[(trifluoromethyl)sulfanyl]phenyl}ethyl]-1,6-dihydropyrimidine-4-carboxamide,

2-(methylamino)-6-oxo-N-[(1R)-1-{4-[(trifluoromethyl)sulfanyl]phenyl}ethyl]-1,6-dihydropyrimidine-4-carboxamide,

2-amino-6-oxo-N-[(1R)-1-{4-[(trifluoromethyl)sulfanyl]phenyl}ethyl]-1,6-dihydropyrimidine-4-carboxamide,

6-oxo-2-pyrrolidin-1-yl-N-[(1R)-1-{4-[(trifluoromethyl)sulfanyl]phenyl}ethyl]-1,6-dihydropyrimidine-4-carboxamide,

N-[(1R)-2-methyl-1-{4-[(trifluoromethyl)sulfanyl]phenyl}propyl]-6-oxo-2-pyrrolidin-1-yl-1,6-dihydropyrimidine-4-carboxamide,

2-azetidin-1-yl-N-[(1R)-2-methyl-1-{4-[(trifluoromethyl)sulfanyl]phenyl}propyl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-{(1R)-1-[3-fluoro-4-(trifluoromethoxy)phenyl]-2-methylpropyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-[(1R)-1-{3-fluoro-4-[(trifluoromethyl)sulfanyl]phenyl}-2-methylpropyl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(1R)-1-[3-fluoro-4-(trifluoromethoxy)phenyl]-2-methylpropyl}-2-(methylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-amino-N-{(1R)-1-[3-fluoro-4-(trifluoromethoxy)phenyl]-2-methylpropyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(methylamino)-N-[(1R)-2-methyl-1-{4-[(trifluoromethyl)sulfanyl]phenyl}propyl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-amino-N-[(1R)-2-methyl-1-{4-[(trifluoromethyl)sulfanyl]phenyl}propyl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-[(1R)-1-{3-fluoro-4-[(trifluoromethyl)sulfanyl]phenyl}-2-methylpropyl]-2-(methylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-amino-N-[(1R)-1-{3-fluoro-4-[(trifluoromethyl)sulfanyl]phenyl}-2-methylpropyl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-amino-N-{(1R)-2,2-dimethyl-1-[4-(trifluoromethyl)phenyl]propyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(1R)-2,2-dimethyl-1-[4-(trifluoromethyl)phenyl]propyl}-2-(methylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(2-methyl-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidin-6-yl)-6-oxo-N-{(1R)-1-[4-(trifluoromethyl)phenyl]ethyl}-1,6-dihydropyrimidine-4-carboxamide,

2-(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-6-oxo-N-{(1R)-1-[4-(trifluoromethyl)phenyl]ethyl}-1,6-dihydropyrimidine-4-carboxamide,

2-(5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidin-6-yl)-6-oxo-N-{(1R)-1-[4-(trifluoromethyl)phenyl]ethyl}-1,6-dihydropyrimidine-4-carboxamide,

2-[(3S)-3-fluoropyrrolidin-1-yl]-N-{(1R)-1-[3-fluoro-4-(trifluoromethoxy)phenyl]-2-methylpropyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-[(3R)-3-fluoropyrrolidin-1-yl]-N-{(1R)-1-[3-fluoro-4-(trifluoromethoxy)phenyl]-2-methylpropyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(3-fluoroazetidin-1-yl)-N-{(1R)-1-[3-fluoro-4-(trifluoromethoxy)phenyl]-2-methylpropyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-[(3S)-3-fluoropyrrolidin-1-yl]-N-[(1R)-1-{3-fluoro-4-[(trifluoromethyl)sulfanyl]phenyl}-2-methylpropyl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(1R)-1-[3-fluoro-4-(trifluoromethoxy)phenyl]-2-methylpropyl}-2-[(3R)-3-hydroxypyrrolidin-1-yl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(R)-cyclopropyl[4-(trifluoromethyl)phenyl]methyl}-2-[(3S)-3-fluoropyrrolidin-1-yl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-[(3S)-3-fluoropyrrolidin-1-yl]-N-{(1R)-1-[3-fluoro-4-(trifluoromethyl)phenyl]-2-methylpropyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(1R)-2,2-dimethyl-1-[4-(trifluoromethyl)phenyl]propyl}-2-[(3S)-3-fluoropyrrolidin-1-yl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(1R)-2,2-dimethyl-1-[4-(trifluoromethyl)phenyl]propyl}-2-[(3S)-3-methoxypyrrolidin-1-yl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

N-{(1R)-2,2-dimethyl-1-[4-(trifluoromethyl)phenyl]propyl}-2-[(3R)-3-methoxypyrrolidin-1-yl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

(R)-2-(dimethylamino)-N-{1,2-dimethyl-1-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]propyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

(S)-2-(dimethylamino)-N-{1,2-dimethyl-1-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]propyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-N-{2-methyl-1-[4-(trifluoromethyl)phenyl]cyclopropyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide (cis, enantiomer A),

2-(dimethylamino)-N-{2-methyl-1-[4-(trifluoromethyl)phenyl]cyclopropyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide (cis, enantiomer B),

(R)-N-{(1R)-2,2-dimethyl-1-[4-(trifluoromethyl)phenyl]propyl}-2-[3-(methoxymethyl)pyrrolidin-1-yl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

(S)-N-{(1R)-2,2-dimethyl-1-[4-(trifluoromethyl)phenyl]propyl}-2-[3-(methoxymethyl)pyrrolidin-1-yl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

6-oxo-2-propoxy-N-{(1R)-1-[4-(trifluoromethyl)phenyl]ethyl}-1,6-dihydropyrimidine-4-carboxamide,

2-(3-methoxypropoxy)-6-oxo-N-{1-[4-(trifluoromethyl)phenyl]ethyl}-1,6-dihydropyrimidine-4-carboxamide,

2-[(1-methylpiperidin-3-yl)oxy]-6-oxo-N-{1-[4-(trifluoromethyl)phenyl]ethyl}-1,6-dihydropyrimidine-4-carboxamide,

2-[3-(1-methylethoxy)propoxy]-6-oxo-N-{1-[4-(trifluoromethyl)phenyl]ethyl}-1,6-dihydropyrimidine-4-carboxamide,

2-(3-methoxy-3-methylbutoxy)-6-oxo-N-{1-[4-(trifluoromethyl)phenyl]ethyl}-1,6-dihydropyrimidine-4-carboxamide,

2-[2-(methylamino)ethoxy]-6-oxo-N-{1-[4-(trifluoromethyl)phenyl]ethyl}-1,6-dihydropyrimidine-4-carboxamide,

6-oxo-2-(tetrahydrofuran-3-yloxy)-N-{1-[4-(trifluoromethyl)phenyl]ethyl}-1,6-dihydropyrimidine-4-carboxamide,

2-[3-(4-methoxyphenoxy)propoxy]-6-oxo-N-{1-[4-(trifluoromethyl)phenyl]ethyl}-1,6-dihydropyrimidine-4-carboxamide,

N-[(1R)-1-(4-cyclopropyl-3-fluorophenyl)-2-methylpropyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-6-oxo-N-{phenyl[4-(trifluoromethyl)phenyl]methyl}-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-6-oxo-N-{pyridin-4-yl[4-(trifluoromethyl)phenyl]methyl}-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-6-oxo-N-{2-oxo-1-[4-(trifluoromethyl)phenyl]propyl}-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-6-oxo-N-[(4R)-7-(trifluoromethyl)-3,4-dihydro-1H-isochromen-4-yl]-1,6-dihydropyrimidine-4-carboxamide,

N-{cyano[4-(trifluoromethyl)phenyl]methyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-6-oxo-N-{1-[4-(trifluoromethoxy)phenyl]cyclobutyl}-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-6-oxo-N-{1-[4-(trifluoromethyl)phenyl]cyclopentyl}-1,6-dihydropyrimidine-4-carboxamide,

N-{2-cyano-1-[4-(trifluoromethyl)phenyl]ethyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-6-oxo-N-[(1S)-6-(trifluoromethyl)-1,2,3,4-tetrahydronaphthalen-1-yl]-1,6-dihydropyrimidine-4-carboxamide,

methyl({[2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-yl]carbonyl}amino)[4-(trifluoromethyl)phenyl]acetate,

2-(dimethylamino)-6-oxo-N-{2,2,2-trifluoro-1-[4-(trifluoromethyl)phenyl]ethyl}-1,6-dihydropyrimidine-4-carboxamide,

2-(dimethylamino)-6-oxo-N-{3-[4-(trifluoromethyl)phenyl]oxetan-3-yl}-1,6-dihydropyrimidine-4-carboxamide,

or a pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a compound of claim 1 or a pharmaceutically acceptable salt or solvate thereof.

Assignments (4)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2017
From: SHEN, DONG-MING; QIAN, XIAOXIA; HARPER, BART; YANG, MENG; WANG, DEPING
To: MERCK SHARP & DOHME CORP.
Reel/Frame 044115/0162 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2017
From: BO, YINGJIAN
To: PHARMARON BEIJING CO. LTD.
Reel/Frame 044115/0293 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2017
From: PHARMARON BEIJING CO. LTD.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 044115/0366 →
Priority Claims (1)
WO PCT/CN2015/079091 · May 15, 2015 · international
Continuity (1)
Related Publication 20180256575A1 · Sep 13, 2018